A Revolution Towards A Cure

We combine precision stem cell engineering, highly-scalable cell manufacturing,

and NK-activating antibodies to unlock the full potential of Natural Killer Cells as the safest, most effective, most broadly-available first line of defense against cancer.


Precision NK therapies have the potential to revolutionize cancer treatment with unsurpassed safety and efficacy. We are excited to bring NK Cell Engager antibodies and CAR-NK cell therapies to initial clinical trials starting in 2021, moving towards broad patient access to cancer-defeating cures."

Dr. Daniel Teper,

Cytovia Therapeutics CEO